Propionic Acid

Propionic Acid

SCHEMBL6723765

CCC(=O)O.CCCCn1cnc2cnc3ccccc3c21

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
MAPT P10636 1/20 0.42
LMNA P02545 1/20 0.42
EGLN3 Q9H6Z9 1/20 0.42
ALDH1A1 P00352 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 1/20 0.41
HPGD P15428 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
POLB P06746 2/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029970 0.91 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DMAPT
Sarcosine SCHEMBL14432675 0.91 LMNA (0.42) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL15924790 0.86 TLR7 (0.47) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL15924453 0.86 TLR7 (0.47) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL10587719 0.86 TLR7 (0.47) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL9602914 0.86 TLR7 (0.47) PDE4APDE4BPDE4CPDE4DMAPT
Propionic Acid SCHEMBL6718880 0.84 SMN1; SMN2 (0.48) LMNASMN1; SMN2POLBTHRB
SCHEMBL5617084 0.84 EGLN3 (0.49) EGLN3ALDH1A1CYP1A2CYP2D6CYP2C9
Propionic Acid SCHEMBL6726633 0.83 TLR7 (0.53) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL10727642 0.82 MPO (0.42) PDE4APDE4BPDE4CPDE4DMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6790961-B2 REACTING A 3-AMINO-4-(SUBSTITUTED)AMINO-2-CHLOROQUINOLINE WITH AN ALKYLCARBONYL CHLORIDE TO FORM THE 2-ALKYLCARBOXAMIDE INTERMEDIATE 3M INNOVATIVE PROPERTIES COMPANY 2004-09-14 US disclosed
US-20040122231-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2004-06-24 US disclosed
US-6686472-B2 Process for preparing 1-substituted, 2-substituted 1-H-imidazo(4,5-c)quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2004-02-03 US disclosed
US-20030212270-A1 Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines 3M INNOVATIVE PROPERTIES COMPANY 2003-11-13 US disclosed
US-6608201-B2 Amidation of a 2-halo-3,4-diaminoquinoline with an acid chloride; dehalogenation, amination with ammonia; cyclization 3M INNOVATIVE PROPERTIES COMPANY 2003-08-19 US disclosed
US-20030119861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2003-06-26 US disclosed
US-6465654-B2 ANTIVIRAL AGENTS, THAT INDUCE BIOSYNTHESIS OF INTERFERON, AND INHIBIT TUMOR FORMATION 3M INNOVATIVE PROPERTIES COMPANY 2002-10-15 US disclosed
US-20020115861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2002-08-22 US disclosed
US-6348462-B1 VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2002-02-19 US disclosed
US-5977366-A 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY (US) 1999-11-02 US disclosed
US-5605899-A VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-02-25 US disclosed
US-5389640-A Viricides, antitumor agents MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212270-A1 Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines IFNAR1, IRF3, IFNG PDE4A 56/4885PDE4B 83/4885PDE4C 91/4885
US-20020115861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines IFNAR1, IFNG, IRF3 PDE4A 83/4885PDE4B 120/4885PDE4C 122/4885
US-20040122231-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines UGT1A4, QARS1, HTR4 PDE4A 247/4885PDE4B 159/4885PDE4C 317/4885
US-20030119861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines IRF3, IFNAR1, IFNG PDE4A 43/4885PDE4B 52/4885PDE4C 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.